Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

XEN®-63 Compared to XEN®-45 Gel Stents to Reduce Intraocular Pressure in Glaucoma

Charlotte Evers
* ORCID logo ,
Daniel Böhringer
,
Sara Kallee
,
Philip Keye
ORCID logo ,
Heiko Philippin
ORCID logo ,
Timothy Piotrowski
,
Thomas Reinhard
,
Jan Lübke
Version 1 : Received: 7 June 2023 / Approved: 7 June 2023 / Online: 7 June 2023 (09:29:59 CEST)

A peer-reviewed article of this Preprint also exists.

Evers, C.; Böhringer, D.; Kallee, S.; Keye, P.; Philippin, H.; Piotrowski, T.; Reinhard, T.; Lübke, J. XEN®-63 Compared to XEN®-45 Gel Stents to Reduce Intraocular Pressure in Glaucoma. J. Clin. Med. 2023, 12, 5043. Evers, C.; Böhringer, D.; Kallee, S.; Keye, P.; Philippin, H.; Piotrowski, T.; Reinhard, T.; Lübke, J. XEN®-63 Compared to XEN®-45 Gel Stents to Reduce Intraocular Pressure in Glaucoma. J. Clin. Med. 2023, 12, 5043.

Abstract

The XEN® gel stent reduces intraocular pressure (IOP) in glaucoma. XEN®-45 is widely used while the newer XEN®-63 has a larger lumen that may lower IOP more. We retrospectively compared the first 15 XEN®-63 cases to 15 matched XEN®-45 controls. With a preoperative IOP of 18.1 ± 3.9 mmHg (mean ± SD) and a final IOP of 9.2 ± 4.2 mmHg, XEN®-63 implantation resulted in an IOP reduction of 48.0 ± 23.3%. Similarly, with a preoperative IOP of 18.3 ± 4.5 mmHg and a final IOP of 10.5 ± 2.3 mmHg, XEN®-45 implantation resulted in an IOP reduction of 39.5 ± 17.81%. The median follow-up period was 57 days for the XEN®-63 group and 183 days for the XEN®-45 group. 5/15 eyes of each group underwent open conjunctival bleb revision within the period of observation. Two eyes of the XEN®-63 group also had secondary glaucoma surgery. In both groups only one eye required restart of antiglaucomatous medication. XEN®-63 and XEN®-45 effectively lower IOP and medication. XEN-63 achieved lower IOP over a short follow-up. Com-plication and revision rates were similar.

Keywords

XEN®-63 gel stent; glaucoma; bleb revision

Subject

Medicine and Pharmacology, Ophthalmology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.